BibSonomy publications for /user/kanefendt/&BibSonomypublrss/user/kanefendt/&BibSonomy RSS feed for /user/kanefendt/&2012-02-16T04:53:07+01:00- Harmonization of strategies for the validation of quantitative analytical procedures. A SFSTP proposal--part IIIhttp://www.bibsonomy.org/bibtex/28bfd52c788e8ee284f85bd2fabadf778/kanefendtkanefendt2010-02-05T11:28:39+01:00& Analytical Calibration Chemistry Clinical France Laboratories Laboratory Medical Pharmaceutical Reference Reproducibility Research Results Societies Standards Techniques data methods numerical of standards statistics <span class="authorEditorList"><a href="/author/Hubert">P. Hubert</a>, <a href="/author/Nguyen-Huu">J. J. Nguyen-Huu</a>, <a href="/author/Boulanger">B. Boulanger</a>, <a href="/author/Chapuzet">E. Chapuzet</a>, <a href="/author/Cohen">N. Cohen</a>, <a href="/author/Compagnon">P. A. Compagnon</a>, <a href="/author/Dewe">W. Dewe</a>, <a href="/author/Feinberg">M. Feinberg</a>, <a href="/author/Laurentie">M. Laurentie</a>, <a href="/author/Mercier">N. Mercier</a>, <a href="/author/Muzard">G. Muzard</a>, <a href="/author/Valat">L. Valat</a>, and <a href="/author/Rozet">E. Rozet</a> </span><em>J.Pharm.Biomed.Anal.</em> <em>45(1):82-96</em> (<em>2007</em>)
- Sunitinib induced hypertension, thrombotic microangiopathy and reversible posterior leukencephalopathy syndromehttp://www.bibsonomy.org/bibtex/2f4e6a5de4f2b9e413dbb8109656c7786/kanefendtkanefendt2010-02-05T11:28:39+01:00& A Aged Agents Antineoplastic Endothelial Factor Female Growth Humans Hypertension Indoles Middle Neurotoxicity Purpura Pyrroles Receptor-2 Syndromes Thrombocytopenic Thrombotic Vascular adverse antagonists chemically effects etiology induced inhibitors <span class="authorEditorList"><a href="/author/Kapiteijn">E. Kapiteijn</a>, <a href="/author/Brand">A. Brand</a>, <a href="/author/Kroep">J. Kroep</a>, and <a href="/author/Gelderblom">H. Gelderblom</a> </span><em>Ann.Oncol.</em> <em>18(10):1745-1747</em> (<em>2007</em>)
- Tumor microvasculature and microenvironment: targets for anti-angiogenesis and normalizationhttp://www.bibsonomy.org/bibtex/2143cacfb64ea0a7986d0ab5e71479dba/kanefendtkanefendt2010-02-05T11:28:39+01:00& Angiogenesis Animals Blood Endothelial Factors Growth Humans Inhibitors Laboratories Neoplasms Neovascularization Pathologic Research Vascular Vessels antagonists blood cells drug inhibitors pathology supply therapeutic therapy use <span class="authorEditorList"><a href="/author/Fukumura">D. Fukumura</a>, and <a href="/author/Jain">R. K. Jain</a> </span><em>Microvasc.Res.</em> <em>74(2-3):72-84</em> (<em>2007</em>)
- Vascular endothelial cell-specific NF-kappaB suppression attenuates hypertension-induced renal damagehttp://www.bibsonomy.org/bibtex/2fe9b6da17080b89b77fd623f65128cf0/kanefendtkanefendt2010-02-05T11:28:39+01:00& Adhesion Albuminuria Angiotensin Animals Atherosclerosis B Blood C57BL Cardiovascular Cell Cells Chain Chloride Cultured Dietary Diseases Endothelial Ester Expression Factor-alpha Fusion Gene Humans Hypertension I-kappa II III Inbred Inflammation Intercellular Kidney Methyl Mice Models Molecule-1 NF-kappa NG-Nitroarginine Necrosis Nephritis Nitric Organ Oxide Polymerase Pressure Proteins Reaction Receptor Recombinant Regulation Research Reverse Signal Sodium Specificity Synthase TIE-1 Transcriptase Transduction Transgenic Tumor Type Vascular antagonists biosynthesis blood cells complications control etiology genetics inhibitors metabolism physiology physiopathology prevention protein toxicity <span class="authorEditorList"><a href="/author/Henke">N. Henke</a>, <a href="/author/Schmidt-Ullrich">R. Schmidt-Ullrich</a>, <a href="/author/Dechend">R. Dechend</a>, <a href="/author/Park">J. K. Park</a>, <a href="/author/Qadri">F. Qadri</a>, <a href="/author/Wellner">M. Wellner</a>, <a href="/author/Obst">M. Obst</a>, <a href="/author/Gross">V. Gross</a>, <a href="/author/Dietz">R. Dietz</a>, <a href="/author/Luft">F. C. Luft</a>, <a href="/author/Scheidereit">C. Scheidereit</a>, and <a href="/author/Muller">D. N. Muller</a> </span><em>Circ.Res.</em> <em>101(3):268-276</em> (<em>2007</em>)
- Sunitinib efficacy against advanced renal cell carcinomahttp://www.bibsonomy.org/bibtex/230fd986fa9ab1ed24fcf59cfe32f7d3c/kanefendtkanefendt2010-02-05T11:28:39+01:00& Administration Adult Aged Agents Antineoplastic Carcinoma Cell Disease Disease-Free Female Follow-Up Humans Indoles Kidney Laboratories Male Method Middle Neoplasm Neoplasms Oral Outcome Progression Pyrroles Rate Renal Research Retrospective Single-Blind Staging States Studies Survival Treatment Tyrosine United administration dosage drug epidemiology methods mortality pathology response therapy <span class="authorEditorList"><a href="/author/Motzer">R. J. Motzer</a>, <a href="/author/Michaelson">M. D. Michaelson</a>, <a href="/author/Rosenberg">J. Rosenberg</a>, <a href="/author/Bukowski">R. M. Bukowski</a>, <a href="/author/Curti">B. D. Curti</a>, <a href="/author/George">D. J. George</a>, <a href="/author/Hudes">G. R. Hudes</a>, <a href="/author/Redman">B. G. Redman</a>, <a href="/author/Margolin">K. A. Margolin</a>, and <a href="/author/Wilding">G. Wilding</a> </span><em>J.Urol.</em> <em>178(5):1883-1887</em> (<em>2007</em>)
- Vascular endothelial growth factor receptor 3 is involved in tumor angiogenesis and growthhttp://www.bibsonomy.org/bibtex/21d3ba1cc74ddebe211f5e063d1db007f/kanefendtkanefendt2010-02-05T11:28:39+01:00& Animals Antibodies Antitumor Assays BALB Binding C Cell D Endothelial Factor Growth Human Humans Immunohistochemistry Inbred Ligands Mice Model Monoclonal Neoplasms Neovascularization Nude Pathologic Processes Receptor-3 Research Vascular Xenograft analysis antagonists blood immunology inhibitors metabolism pharmacology supply therapy <span class="authorEditorList"><a href="/author/Laakkonen">P. Laakkonen</a>, <a href="/author/Waltari">M. Waltari</a>, <a href="/author/Holopainen">T. Holopainen</a>, <a href="/author/Takahashi">T. Takahashi</a>, <a href="/author/Pytowski">B. Pytowski</a>, <a href="/author/Steiner">P. Steiner</a>, <a href="/author/Hicklin">D. Hicklin</a>, <a href="/author/Persaud">K. Persaud</a>, <a href="/author/Tonra">J. R. Tonra</a>, <a href="/author/Witte">L. Witte</a>, and <a href="/author/Alitalo">K. Alitalo</a> </span><em>Cancer Res.</em> <em>67(2):593-599</em> (<em>2007</em>)
- Cardiotoxicity associated with tyrosine kinase inhibitor sunitinibhttp://www.bibsonomy.org/bibtex/2506ad4630500172729537a9ce24caf9c/kanefendtkanefendt2010-02-05T11:28:39+01:00& Aged Agents Animals Antineoplastic Arteries Artery Blood Carcinoma Coronary Disease Failure Female Gastrointestinal Heart Humans Hypertension Indoles Kinase Kinases Male Mice Middle Multicenter Pressure Protein-Tyrosine Pyrroles Rats Research Retrospective Safety Stroke Stromal Studies Topic Tumors Tyrosine Volume adverse antagonists as blood chemically drug effects induced inhibitors methods therapeutic therapy toxicity use <span class="authorEditorList"><a href="/author/Chu">T. F. Chu</a>, <a href="/author/Rupnick">M. A. Rupnick</a>, <a href="/author/Kerkela">R. Kerkela</a>, <a href="/author/Dallabrida">S. M. Dallabrida</a>, <a href="/author/Zurakowski">D. Zurakowski</a>, <a href="/author/Nguyen">L. Nguyen</a>, <a href="/author/Woulfe">K. Woulfe</a>, <a href="/author/Pravda">E. Pravda</a>, <a href="/author/Cassiola">F. Cassiola</a>, <a href="/author/Desai">J. Desai</a>, <a href="/author/George">S. George</a>, <a href="/author/Morgan">J. A. Morgan</a>, <a href="/author/Harris">D. M. Harris</a>, <a href="/author/Ismail">N. S. Ismail</a>, <a href="/author/Chen">J. H. Chen</a>, <a href="/author/Schoen">F. J. Schoen</a>, <a href="/author/van den Abbeele">A. D. van den Abbeele</a>, <a href="/author/Demetri">G. D. Demetri</a>, <a href="/author/Force">T. Force</a>, and <a href="/author/Chen">M. H. Chen</a> </span><em>Lancet</em> <em>370(9604):2011-2019</em> (<em>2007</em>)
- Surrogate predictive biomarkers for response to anti-EGFR agents: state of the art and challengeshttp://www.bibsonomy.org/bibtex/277bee5565bfa32594d200c2c9fedca93/kanefendtkanefendt2010-02-05T11:28:39+01:00& Antibodies Biological Carcinoma Dosage Drug Epidermal Factor Gene Growth Human Humans Immunohistochemistry Inhibitors Kinase Kinases Lung Markers Monoclonal Mutation Neoplasm Neoplasms Non-Small-Cell Phosphoproteins Predictive Protein Protein-Tyrosine Proteins Proto-Oncogene Quinazolines Receptor Resistance Tests Tyrosine Value analysis antagonists c-akt drug effects erbB-2 erbB-3 genetics identify inhibitors of protein response therapeutic therapy use <span class="authorEditorList"><a href="/author/Cappuzzo">F. Cappuzzo</a>, <a href="/author/Toschi">L. Toschi</a>, <a href="/author/Finocchiaro">G. Finocchiaro</a>, <a href="/author/Ligorio">C. Ligorio</a>, and <a href="/author/Santoro">A. Santoro</a> </span><em>Int.J.Biol.Markers</em> <em>22(1 Suppl 4):S10-S23</em> (<em>2007</em>)
- Severe cardiomyopathy in a patient with renal cell carcinoma after treatment with the novel tyrosine kinase inhibitor sunitinibhttp://www.bibsonomy.org/bibtex/2beabba54bd2d560c3e6e69f70f2777bd/kanefendtkanefendt2010-02-05T11:28:39+01:00& Aged Agents Angiogenesis Antineoplastic Carcinoma Cardiomyopathies Cell Dysfunction Echocardiography Female Humans Illness Index Indoles Inhibitors Kidney Kinase Kinases Left Neoplasms Protein-Tyrosine Pyrroles Renal Severity Tyrosine Ventricular adverse antagonists chemically contraindications drug effects induced inhibitors of therapy <span class="authorEditorList"><a href="/author/Chorianopoulos">E. Chorianopoulos</a>, <a href="/author/Jager">D. Jager</a>, <a href="/author/Katus">H. A. Katus</a>, and <a href="/author/Frey">N. Frey</a> </span><em>Clin.Res.Cardiol.</em> <em>96(11):829-830</em> (<em>2007</em>)
- Appropriate calibration curve fitting in ligand binding assayshttp://www.bibsonomy.org/bibtex/2bc2ca7992c0575aea1a335cb36445dc3/kanefendtkanefendt2010-02-05T11:28:39+01:00& Algorithms Analytical Binding Calibration Chemistry Dose-Response Drug Ligands Models Pharmaceutical Pharmacokinetics Preparations Protein RANGE Relationship Reproducibility Research Results Sensitivity Specificity Statistical analysis and data metabolism methods numerical of response statistics <span class="authorEditorList"><a href="/author/Findlay">J. W. Findlay</a>, and <a href="/author/Dillard">R. F. Dillard</a> </span><em>AAPS.J.</em> <em>9(2):E260-E267</em> (<em>2007</em>)
- Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibitionhttp://www.bibsonomy.org/bibtex/2602435fc1730c5168f565863b795701d/kanefendtkanefendt2010-02-05T11:28:39+01:00& Adaptor Antibodies Benzenesulfonates Biological Delivery Diseases Drug Enzyme Heart Human Humans Indoles Inhibitors Kinase Kinases Models Monoclonal Mutation Neoplasms Protein Protein-Tyrosine Proteins Proto-Oncogene Pyridines Pyrroles Quinazolines Research Signal Systems Transducing Tyrosine adverse antagonists c-abl cells chemically development drug effects growth induced inhibitors physiology protein response therapy toxicity <span class="authorEditorList"><a href="/author/Force">T. Force</a>, <a href="/author/Krause">D. S. Krause</a>, and <a href="/author/van Etten">R. A. van Etten</a> </span><em>Nat.Rev.Cancer</em> <em>7(5):332-344</em> (<em>2007</em>)
- Multiple circulating proangiogenic factors induced by sunitinib malate are tumor-independent and correlate with antitumor efficacyhttp://www.bibsonomy.org/bibtex/2ef0f98aaa58251a4ab8b2c0be419ef9e/kanefendtkanefendt2010-02-05T11:28:39+01:00& A Administration Agents Angiogenesis Animals Antineoplastic Antitumor Assays Blood Cell Dose-Response Drug Endothelial Factor Female Growth Humans Hypoxia Indoles Inducing Line Mice Model Neoplasms Organ Outcome Placenta Pregnancy Proteins Pyrroles RANGE Receptor-2 Relationship Research Schedule Scid Specificity Treatment Tumor Tyrosine Vascular Xenograft administration blood dosage drug effects metabolism pathology pharmacology protein response therapy toxicity <span class="authorEditorList"><a href="/author/Ebos">J. M. Ebos</a>, <a href="/author/Lee">C. R. Lee</a>, <a href="/author/Christensen">J. G. Christensen</a>, <a href="/author/Mutsaers">A. J. Mutsaers</a>, and <a href="/author/Kerbel">R. S. Kerbel</a> </span><em>Proc.Natl.Acad.Sci.U.S.A</em> <em>104(43):17069-17074</em> (<em>2007</em>)
- Molecular basis for sunitinib efficacy and future clinical developmenthttp://www.bibsonomy.org/bibtex/253e1171b8a15a9f6bacf8979fae3a8bb/kanefendtkanefendt2010-02-05T11:28:39+01:00& A Angiogenesis Animals Carcinoma Clinical Design Drug Endothelial Factor France Growth Humans Indoles Inhibitors Kinase Kinases Neoplasm Neoplasms Protein-Tyrosine Pyrroles Receptors Resistance Topic Trials Tyrosine Vascular adverse antagonists as biosynthesis blood drug effects enzymology inhibitors metabolism pharmacology response supply therapeutic therapy use <span class="authorEditorList"><a href="/author/Faivre">S. Faivre</a>, <a href="/author/Demetri">G. Demetri</a>, <a href="/author/Sargent">W. Sargent</a>, and <a href="/author/Raymond">E. Raymond</a> </span><em>Nat.Rev.Drug Discov.</em> <em>6(9):734-745</em> (<em>2007</em>)
- Molecular regulation of tumor angiogenesis: mechanisms and therapeutic implicationshttp://www.bibsonomy.org/bibtex/216cb496208ca695d0d314b31867b1929/kanefendtkanefendt2010-02-05T11:28:39+01:00& Angiogenesis Capillaries Human Humans Inhibitors Neoplasms Neovascularization Pathologic Research blood control drug metabolism pathology pharmacology prevention supply therapeutic therapy use <span class="authorEditorList"><a href="/author/Harper">J. Harper</a>, and <a href="/author/Moses">M. A. Moses</a> </span><em>EXS</em> (<em>2006</em>)
- The clinical toxicity profile of vascular endothelial growth factor VEGF and vascular endothelial growth factor receptor VEGFR targeting angiogenesis inhibitors; a reviewhttp://www.bibsonomy.org/bibtex/2369c88f24f6cf696fc67db33cc272b4f/kanefendtkanefendt2010-02-05T11:28:39+01:00& A Angiogenesis Antibodies Endothelial Factor Growth Humans Inhibitors Kinase Kinases Medical Monoclonal Neoplasms Neovascularization Oncology Pathologic Protein Protein-Tyrosine Receptors Tyrosine Vascular adverse antagonists blood control drug effects inhibitors prevention protein supply therapy toxicity <span class="authorEditorList"><a href="/author/Eskens">F. A. Eskens</a>, and <a href="/author/Verweij">J. Verweij</a> </span><em>Eur.J.Cancer</em> <em>42(18):3127-3139</em> (<em>2006</em>)
- Tyrosine kinase inhibitors of vascular endothelial growth factor receptors in clinical trials: current status and future directionshttp://www.bibsonomy.org/bibtex/2a983fe521c531b49f0265112de4eeb86/kanefendtkanefendt2010-02-05T11:28:39+01:00& A Angiogenesis Clinical Endothelial Factor Growth Human Humans Inhibitors Kinase Kinases Lung Neoplasms Piperidines Protein Protein-Tyrosine Proteins Quinazolines Receptors Research Safety Topic Trials Tyrosine Vascular antagonists as drug inhibitors metabolism protein therapeutic therapy use <span class="authorEditorList"><a href="/author/Morabito">A. Morabito</a>, <a href="/author/De">Maio E. De</a>, <a href="/author/Di">Maio M. Di</a>, <a href="/author/Normanno">N. Normanno</a>, and <a href="/author/Perrone">F. Perrone</a> </span><em>Oncologist.</em> <em>11(7):753-764</em> (<em>2006</em>)
- Regulation of cardiac growth and coronary angiogenesis by the Akt/PKB signaling pathwayhttp://www.bibsonomy.org/bibtex/2c24011977ff0738124791c547dd0d0d9/kanefendtkanefendt2010-02-05T11:28:39+01:00& Adaptation Animals Cardiac Cardiomegaly Cell Contraction Differentiation Diseases Failure Growth Heart Humans Hypertension Myocardial Myocytes Neovascularization Physiologic Physiological Proteins Proto-Oncogene Signal Sports Transduction c-akt cytology development embryology genetics growth metabolism pathology physiology physiopathology protein <span class="authorEditorList"><a href="/author/Shiojima">I. Shiojima</a>, and <a href="/author/Walsh">K. Walsh</a> </span><em>Genes Dev.</em> <em>20(24):3347-3365</em> (<em>2006</em>)
- Notch signaling in the regulation of tumor angiogenesishttp://www.bibsonomy.org/bibtex/267ae74502331a25b179814c5fd6bc59c/kanefendtkanefendt2010-02-05T11:28:39+01:00& Agents Angiogenesis Animals Binding Biological Blood Carcinogens Cells Endothelial Genes Humans Inducing Inhibitors Laboratories Ligands Models Neoplasms Neovascularization Notch Pathologic Receptors Signal Suppressor Transduction Tumor Vessels blood cells development growth metabolism physiology supply therapy <span class="authorEditorList"><a href="/author/Rehman">A. O. Rehman</a>, and <a href="/author/Wang">C. Y. Wang</a> </span><em>Trends Cell Biol.</em> <em>16(6):293-300</em> (<em>2006</em>)
- Possible molecular mechanisms involved in the toxicity of angiogenesis inhibitionhttp://www.bibsonomy.org/bibtex/2463d0b247e477cd3460c6d76976388b8/kanefendtkanefendt2010-02-05T11:28:39+01:00& A Administration Agents Angiogenesis Antineoplastic Biological Blood Clinical Coagulation Drug Endothelial Factor Function Growth Humans Hypertension Inhibitors Left Models Neoplasm Platelets Research Resistance Schedule Signal Thrombosis Topic Transduction Trials Vascular Ventricular administration adverse antagonists as chemically dosage drug effects etiology induced inhibitors physiology toxicity <span class="authorEditorList"><a href="/author/Verheul">H. M. Verheul</a>, and <a href="/author/Pinedo">H. M. Pinedo</a> </span><em>Nat.Rev.Cancer</em> <em>7(6):475-485</em> (<em>2007</em>)
- Circulating VEGF reduction, response and outcome in advanced colorectal cancer patients treated with cetuximab plus irinotecanhttp://www.bibsonomy.org/bibtex/223511f1ba021049533daca96017b211a/kanefendtkanefendt2010-02-05T11:28:39+01:00& A Adult Aged Antibodies Antineoplastic Biological Camptothecin Chemotherapy Colorectal Combined Disease Endothelial Factor Female Growth Humans Male Markers Medical Middle Monoclonal Neoplasms Oncology Outcome Progression Prospective Protocols Rate Studies Survival Treatment Tumor Vascular administration analogs antagonists blood derivatives dosage drug inhibitors methods mortality response therapeutic therapy trends use <span class="authorEditorList"><a href="/author/Vincenzi">B. Vincenzi</a>, <a href="/author/Santini">D. Santini</a>, <a href="/author/Russo">A. Russo</a>, <a href="/author/Gavasci">M. Gavasci</a>, <a href="/author/Battistoni">F. Battistoni</a>, <a href="/author/Dicuonzo">G. Dicuonzo</a>, <a href="/author/Rocci">L. Rocci</a>, <a href="/author/Rosaria">V. M. Rosaria</a>, <a href="/author/Gebbia">N. Gebbia</a>, and <a href="/author/Tonini">G. Tonini</a> </span><em>Pharmacogenomics.</em> <em>8(4):319-327</em> (<em>2007</em>)